U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07084662) titled 'Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma' on July 09.
Brief Summary: To evaluate the efficacy and safety of Xinlikang capsule in the treatment of cancer-related fatigue (CRF) and peripheral blood lymphocytes in patients with diffuse large B-cell lymphoma (DLBCL) who achieved complete remission (CR) after all courses of chemotherapy-containing regimens
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention:
DRUG: Xinlikang capsules
Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 week...